1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 15 SEPTEMBER 2014

CNS Drug News 15 SEPTEMBER 2014

  • September 2014
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - FDA-Approved Contrave Enters Tough And Competitive Market
Industry Trend Analysis - Nuplazid's FDA Breakthrough Therapy Designation Boosts ACADIA
Industry Brief - Phase IIa Study Of NeuroDerm's Liquid Levodopa/Carbidopa For PD Commences
Industry Brief - Avanir Reports Positive AVP-923 Phase II Results For Agitation In AD Patients
Industry Brief - GeNeuro Reports Positive Results From GNbAC1 Phase IIa Trial In MS
Industry Trend Analysis - Calico Collaboration To Further Expand AbbVie's Portfolio
Industry Brief - FDA Grants ODD To Prana's PBT2 For HD
Industry Brief - Evotec/CHDI Extend Collaboration
Industry Brief - KineMed Receives US Patent Allowance For Noscapine to Treat ALS/PD/DN
Industry Brief - OB Halts Oxycyte Phase IIb TBI Trial
Industry Brief - Meiji/Takeda Finalise Co-Promotion Agreement For Rozerem In Japan
Industry Brief - Teva Launches Escitalopram In Canada
Industry Brief - Lannett Gains US Oxycodone Approval
Industry Brief - First Patient Enrolled In MDX Phase IIb Trial In Adolescents With ADHD
Industry Brief - Mallinckrodt's MNK-155 Shows Efficacy In Phase III Acute Pain Trial
Industry Brief - Acura Submits Formal Dispute Resolution Request With FDA
Industry Brief - Court Overturns Dexmedetomidine Temporary Restraining Order
Industry Brief - Depomed Summary Judgment Motion Granted In Gralise Orphan Drug Exclusivity Suit
Industry Brief - New NIDA Grant Awarded For MN-166 In Opioid Dependence
Industry Brief - Eisai Sells US/Puerto Rican Zonegran Rights To Concordia
Industry Brief - Ligand Licenses Captisol-enabled Lamotrigine To CURx
Industry Brief - FDA Accepts Vyvanse sNDA For Filing With Priority Review
Industry Trend Analysis - Tesaro's Rolapitant On Course To Compete With Merck's Emend In 2015
Industry Brief - Opexa Commences OPX-212 Development Programme In NMO
Industry Brief - CNS Conferences - December 2014

Table Of Contents

CNS Drug News 15 SEPTEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.